The compared management of duodenal ulcer between esomeprazole and omeprazole

Objective-. Proton pump inhibitor (PPI)-based triple therapy is recognized ad the best therapeutics on he Helicobacter pylori. associated peptic ulcer. Esomeprazole is the newest PPIs. The purpose of this study was to compare the efficacy of esomeprazole or omeprazole at eradicating of H. pylori the cicatrisation of ulcer and the control of clinic symptoms. Methods: A total of 60 H. pylori-positive patients with acute duodenal ulcer (DU) received twice daily treatment with esomeprazile 20 mg (n =30) or omeprazole 20 mg in =30) in combination with amoxicilin 1 g and clarithromycin 500 mg for 1 week. After completion of therapy 4 weeks later, we compared the ulcer healing, Hp status and the clinical symptom between two groups. Ulcer healing was assessed by endoscopy, and Hp status was assessed by 14C-ure breath testings. Results: The Hp eradication rates(95%CI) were: EAC90% (73%-98%) ; OAC80% (61%-92%). The esomeprazole-based triple therapy can better control gastric symptoms (upper abdominal pain, heartburn, acid reflux) than omeprazole-based triple therapy, and the data has statistical correlation. Conclusions:Esomeprazole-based triple therapy has the same effect with omeprazole-based triple therapy for ulcer healing and Hp eradication in patients with DU disease,and esomeprazole-based triple therapy has a more efficacy for gastric symptoms (upper abdominal pain, heartburn, acid reflux) control.